New malaria drug interaction study launches in healthy volunteers

NCT ID NCT07670377

Recruiting now Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This early-stage study will check if a new experimental drug for malaria, called GSK3772701, changes how the body processes other medications. Twenty healthy adults aged 18 to 55 will take both GSK3772701 and a common probe drug called midazolam. The goal is to see if GSK3772701 speeds up or slows down the breakdown of other drugs, which is important for safe use in future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK3772701 and midazolam
What this could lead to: If successful, this study will help doctors understand whether GSK3772701 can be safely taken with other medications, potentially guiding future malaria treatment combinations.
What could go wrong: This is a very early, small study in healthy volunteers, not in malaria patients. It only measures drug interactions, not whether GSK3772701 works against malaria. Results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA,FALCIPARUM

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.